NCT03923881 (OPUS) is a NA clinical trial of MSOT Acuity Echo in Oral Cancer, sponsored by University Medical Center Groningen.

Who is sponsoring NCT03923881?

NCT03923881 is sponsored by University Medical Center Groningen.

What drugs are being tested in NCT03923881?

Interventions in NCT03923881: MSOT Acuity Echo.

What condition does NCT03923881 study?

NCT03923881 studies Oral Cancer, Lymph Node Metastases.

Is NCT03923881 still recruiting?

NCT03923881 is currently status unknown. Last updated 3 May 2021.

Last reviewed 2021-05-03 · How we verify

NCT03923881: OPUS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MSOT Using Cetuximab-800CW for Detection of Cervical Lymph Node Metastases

Status unknown NA Last updated 3 May 2021

What this trial tests

NA trial testing MSOT Acuity Echo in Oral Cancer in 20 participants. Status unknown.

Timeline

11 April 2019

Primary endpoint
30 July 2021

30 September 2021

Quick facts

Lead sponsor	University Medical Center Groningen
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	diagnostic
Enrollment	20
Start date	11 April 2019
Primary completion	30 July 2021
Estimated completion	30 September 2021
Sites	1 location across Netherlands

Drugs / interventions tested

MSOT Acuity Echo

Conditions studied

Oral Cancer — all drugs for Oral Cancer →
Lymph Node Metastases — all drugs for Lymph Node Metastases →

Sponsor

University Medical Center Groningen

Who can join

18 and older, any sex, with Oral Cancer or Lymph Node Metastases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The presence of lymph node metastasis is an important factor in determining the appropriate treatment plan in patients with OSCC. However, detection of lymph node metastases by means of current imaging modalities is limited. 20-30% of patients with a clinically negative neck (cN0) harbour lymph node metastasis that were not detected during clinical diagnostic workup, which are referred to as occult lymph node metastasis. Therefore, patients with a risk of lymph node metastasis higher than 20% undergo a sentinel node procedure (SNP) or elective neck dissection (END), which means that a substantial part of patients is overtreated. There is need for an additional non-invasive diagnostic tool that can identify lymph node metastasis and thereby support the decision making for treatment of the neck. The main objective of this study is to evaluate if EGFR-positive cervical lymph node metastasis can be detected non-invasively with multispectral optoacoustic imaging using cetuximab-800CW as contrast agent in patients with oral squamous cell carcinoma.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

An Indocyanine Green-Based Nanoprobe for In Vivo Detection of Cellular Senescence.
Baker AG, Hartono M, Ou HL, Popov AB, et al · · 2024 · cited 21× · PMID 38622059 · DOI 10.1002/anie.202404885
Infrared Fluorescence-guided Surgery for Tumor and Metastatic Lymph Node Detection in Head and Neck Cancer.
White HW, Naveed AB, Campbell BR, Lee YJ, et al · · 2024 · cited 6× · PMID 38940689 · DOI 10.1148/rycan.230178
World Molecular Imaging Congress 2022.
· 2022 · cited 2× · PMID 36648635 · DOI 10.1007/s11307-022-01794-2

Verify or expand the search:

Other trials of MSOT Acuity Echo

Trials testing the same drug.

NCT05902884 — New Biomarkers in Facioscapulohumeral Muscular Dystrophy, Multispectral Optoacoustic Tomography. · NA · unknown
NCT04730726 — In Vivo Multispectral Optoacoustic Imaging of Thyroid Nodules · NA · unknown

Other recruiting trials for Oral Cancer

Currently open trials in the same condition.

NCT07509619 — AI-based Physiotherapy Evaluation System for Range of Motion in Oral Cancer Patients · recruiting
NCT07260344 — Evaluation of Two Non-Invasive Methods, High-Resolution Microendoscopy and Liquid-Based Cytology, for Detection of Oral · NA · recruiting
NCT06682494 — Enhancing Oral Cancer Awareness · NA · recruiting
NCT07095608 — Defining TRPV4 Contribution of Schwann Cells to Oral Cancer Pain · NA · recruiting
NCT07296250 — Circulating Tumor Cell Counts in Postoperative ENE-Positive Oral Cavity Cancer Patients After Adjuvant CCRT · NA · recruiting

Other University Medical Center Groningen trials

Trials by the same sponsor.

NCT06647602 — Thyroid Hormone Replacement After Radio Iodine: Value and Efficacy · not yet recruiting
NCT06809946 — Feasibility of Fluorescence Imaging With Bevacizumab-800CW During Bronchoscopy · Phase 2 · not yet recruiting
NCT07527390 — CANagliflozin In DIALysis Patients · Phase 4 · not yet recruiting
NCT07439237 — Implant-supported Maxillary Overdentures; a 15-years Evaluation · not yet recruiting
NCT07275437 — Effectiveness and Safety of Uptitration of Guideline Directed MEdical Therapy in Heart Failure With Reduced Ejection Fra · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03923881 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University Medical Center Groningen
Last refreshed: 3 May 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03923881.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing